The STEP 1 trial studied semaglutide 2.4 mg weekly in adults without diabetes and found 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks
The Ozempic Lawsuit focuses on claims that the diabetes and weight loss medication, Ozempic, has caused severe gastrointestinal issues, including gastroparesis (paralysis of the stomach), nausea, vomiting, and other serious side effects
According to NICE guidance on type 2 diabetes management, regular monitoring and individualised treatment adjustments are essential to optimise outcomes whilst minimising adverse effects
Myth #2: Everyone experiences significant GI problems While GI side effects are common, they're not necessarily severe or even universal
found that the minor A allele was associated with lower glycemic response to subcutaneous GLP-1RAs (semaglutide, liraglutide, dulaglutide)
GLP-1 stands for glucagon-like peptide-1, a natural hormone produced by the body that helps regulate blood sugar, appetite, and digestion